Intradigm

Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of Intradigm RNAi platform. In particular, the company proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.